TrialNature medicine2024

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results.

Jeffrey Sevigny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.